Precision therapeutics for major unmet medical needs
About Us
Changing the way we treat disease
Our approach leverages translational insights and extensive clinical experience to better understand and treat dementia and other disorders. We have a decade of data informing our strategy including patient responder analyses, rigorous dose modeling and flawless clinical execution. As a result, our therapeutic candidates have maximum potential for patient impact.
News & Events
Lighthouse Pharmaceuticals Receives $49.2 Million Grant from NIA to Advance Phase 2 Study of LHP588 for P. gingivalis-Positive Alzheimer’s Disease
- Groundbreaking Clinical Trial to Enroll 300 Patients in Double-Blind, Placebo-Controlled Study of Lysine-Gingipain Inhibitor
Lighthouse Pharmaceuticals Initiates Phase 2 SPRING Trial of LHP588 in P. gingivalis-Positive Alzheimer’s Disease
48-Week Study to Evaluate the Safety and Efficacy of Oral LHP588 Dosed Once Daily
FDA Approval to Proceed with Phase 2 SPRING Trial of LHP588, a Next-Generation Treatment for P. gingivalis-Positive Alzheimer’s Disease
- Phase 1 single ascending and multiple ascending dose studies previously completed demonstrate safety, tolerability and dosing to reach optimal target engagement
Lighthouse Announces Progression of LHP588 Clinical Development Program in Alzheimer's Disease
- Pre-IND meeting completed with US FDA.
-World-class clinical advisory board to support clinical development plans
